Dare Bioscience Inc 주요 수익원은 Women's Health이며, 최신 수익 발표에서 수익은 9,784입니다. 지역별로는 United States이 Dare Bioscience Inc의 주요 시장이며, 수익은 9,784입니다.
Dare Bioscience Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Dare Bioscience Inc의 순손실은 $0입니다.
Dare Bioscience Inc에 부채가 있나요?
no, Dare Bioscience Inc의 부채는 0입니다.
Dare Bioscience Inc의 발행 주식은 몇 주인가요?
Dare Bioscience Inc의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$2.25
시가
$2.27
일일 범위
$2.25 - $2.48
52주 범위
$1.27 - $9.19
거래량
296.8K
평균 거래량
384.2K
배당수익률
--
EPS(TTM)
-0.88
시가총액
$34.0M
DARE란 무엇인가요?
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.